

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



中生北控生物科技股份有限公司
BIOSINO BIO-TECHNOLOGY AND SCIENCE INCORPORATION
(a joint stock limited company incorporated in the People's Republic of China with limited liability)
(Stock Code: 8247)

INSIDE INFORMATION
INDICATIVE ANNOUNCEMENT IN RELATION TO
SIGNING AND COMPLETION OF
THE SHARE TRANSFER AGREEMENT

This announcement is made by Biosino Bio-Technology and Science Incorporation (the “**Company**”) pursuant to Rule 17.10(2)(a) of the Rules (the “**GEM Listing Rules**”) Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions (as defined in the GEM Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

References are made to the Company’s inside information announcements dated 14 March 2023 and 17 March 2023 (the “**Announcements**”), respectively, regarding, among others, that Beijing Enterprises Holdings Limited (“**Beijing Enterprises**”), a substantial shareholder of the Company, is considering to transfer certain H shares of the Company by way of a public solicitation of transferees. Unless otherwise stated, capitalised terms used herein shall have the same meanings defined in the Announcements.

I. THE SHARE TRANSFER AND THE COMPLETION

On 5 May 2023, Beijing Enterprises signed the Share Transfer Agreement with HK Zhixin Investment Co., Limited (“**HK Zhixin**”).

Pursuant to the Share Transfer Agreement, Beijing Enterprises agreed to transfer 27,256,143 H shares (representing approximately 42.40% of the number of issued H shares and 18.84% of the total number of issued shares of the Company as at the date of this announcement) to HK Zhixin at the price of RMB1.77 per H share with a total consideration of RMB48,243,373.11.

The Company was informed by Beijing Enterprises that the completion of the Share Transfer with HK Zhixin under the Share Transfer Agreement (the “**Completion**”) took place on 29 May 2023. Immediately following the Completion and as at the date of this announcement, HK Zhixin holds 27,256,143 H shares, representing approximately 42.40% of the total number of issued H shares and 18.84% of the total number of issued shares of the Company.

II. BASIC INFORMATION ON TRANSFEREE OF THE SHARE TRANSFER

Name of transferee:	HK Zhixin Investment Co., Limited (香港智昕投資有限公司)
Place of incorporation:	Hong Kong
Business nature:	Investment holding

As at the date of this announcement, HK Zhixin is wholly owned by 海南智昕投資合夥企業(有限合夥)(Hainan Zhixin Investment Partnership (Limited Partnership)*), which is owned as to approximately 3.11% by Qiu Zhefeng (邱哲豐) as the general partner, and as to approximately 36.01%, 36.01%, 18.66%, 2.07% and 4.14% by Yan Kang (閔康), Li Dongfeng (李東風), Zhao Qianni (趙倩妮), Wang Ying (王穎) and Huang Zhifen (黃治芬), respectively, as the limited partners.

To the best of the Directors’ knowledge, information and belief, and after making all reasonable enquiries, save for becoming a substantial shareholder of the Company following the Share Transfer, each of HK Zhixin and its ultimate beneficial owners is a third party who is independent from the Company and its connected persons (as defined under the GEM Listing Rules).

III. EFFECTS OF THE SHARE TRANSFER ON THE COMPANY

As of the date of signing of the Share Transfer Agreement, the Company had 64,286,143 H shares in issue. Upon the Completion:

1. Beijing Enterprises do not hold any H shares of the Company; and

2. 30,250,000 H shares of the Company are held by the public, representing approximately 47.06% of the total number of issued H shares of the Company. Accordingly, the Company satisfies the minimum public float requirement of 25% as set out in Rule 11.23(7) of the GEM Listing Rules.

For and on behalf of the Board
Biosino Bio-Technology and Science Incorporation
Wu Lebin
Chairman and Executive Director

Beijing, the PRC, 29 May 2023

As at the date of this announcement, the Board comprises:

Chairman and executive Director

Mr. Wu Lebin (吳樂斌先生)

Vice chairmen and non-executive Directors

Dr. Sun Zhe (孫哲博士) and Mr. Chen Zhengyong (陳正永先生)

President and executive Director

Mr. Chen Peng (陳鵬先生)

Non-executive Directors

Mr. Li Zhonghua (李忠華先生) and Dr. Gao Guangxia (高光俠博士)

Independent non-executive Directors

Prof. Shen Zuojun (沈佐君教授), Mr. Lu Qi (陸琪先生) and Prof. Shen Jiangang (沈劍剛教授)

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief, (1) the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive; and (2) there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Listed Company Information” page of the website of the Stock Exchange at www.hkexnews.hk for at least 7 days from the date of its posting and on the website of the Company at www.zhongsheng.com.cn.